{"id":647815,"date":"2023-04-18T18:28:01","date_gmt":"2023-04-18T18:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=647815"},"modified":"2023-04-18T18:28:01","modified_gmt":"2023-04-18T18:28:01","slug":"pancreatic-ductal-adenocarcinoma-clinical-trials-emerging-therapies-key-companies-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pancreatic-ductal-adenocarcinoma-clinical-trials-emerging-therapies-key-companies-pipeline-analysis-report-2023-delveinsight_647815.html","title":{"rendered":"Pancreatic Ductal Adenocarcinoma Clinical Trials, Emerging Therapies, Key Companies | Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"
\n
\"Pancreatic<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cPancreatic Ductal Adenocarcinoma – Pipeline Insight, 2023,\u201d report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s “Pancreatic Ductal Adenocarcinoma – Pipeline Insight, 2023,<\/a><\/strong>” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. <\/p>\n

Pancreatic Ductal Adenocarcinoma Overview<\/strong><\/p>\n

Pancreatic ductal adenocarcinoma is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, most patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature. There is a lack of simple, early detection methods, and is typically diagnosed at a late stage because symptoms do not appear until the disease has progressed and metastasized to distinct sites. The major difficulties in treating pancreatic cancer lie at both the genetic and cellular levels. The extent of mutational changes in pancreatic tumors generates gene instability that appears to play an essential role in PDAC tumor growth and treatment resistance.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

Key Companies Working in the Pancreatic Ductal Adenocarcinoma Market Includes<\/strong><\/p>\n